Illustrative image – not actual.
Biocon’s contract research arm, Syngene International has lined up USD 200 million (around Rs 1,342 crore) capex to bolster its manufacturing capabilities over the next three years.
The company plans to invest USD 100 million (around Rs 665.27 crore) at a greenfield facility in Mangaluru, the first phase of which will be operationalised by the financial year 2018-19.
Besides, it has also earmarked another USD 100 million to create additional infrastructure at its existing facility at Bengaluru. The first phase of the facility is expected to be completed by 2018-19.
Syngene offers integrated drug discovery and development services with capabilities in medicinal chemistry, biology and toxicology.
